Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resimmune with Ionizing Radiation in Stage IV Melanoma
NCT01888081Phase 2Terminated
- Sponsor
- Angimmune LLC
- Start
- Feb 2014
- Primary completion
- Dec 2020
- Modality
- Immunotoxins, Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of A-dmDT390-bisFv(UCHT1) in melanoma, sponsored by Angimmune LLC. Primary endpoints: Immune-related overall response rate at 1 year and Safety of combining Resimmune with palliative radiation. Started Feb 2014; status: terminated.
02
Drugs
A-dmDT390-bisFv(UCHT1)
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01888081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01888081.